Briefs: Panacea Biotec and Shukra Pharmaceuticals

Panacea Biotec receives acceptance from CMSS for supply of bOPV

Briefs: Panacea Biotec, Lotus Eye Hospital and Uflex

Panacea Biotec receives Rs. 315 crore LoA from UNICEF

Panacea Biotec reaches settlement with Apotex

Apotex will also pay US$ 2.5 million upon receipt of final USFDA approval of the ANDA that is the subject of the Collaboration Agreement for Paclitaxel Protein-Bound Particles for Injectable Suspension

Briefs: Ami Organics and Panacea Biotec

Ami Organics’ Ankleshwar Unit II gets GMP compliant by PMDA Japan

Briefs: Panacea Biotec and Shelter Pharma

Panacea Biotec and Sanofi reached settlement agreement for Shan6

Sanofi would not manufacture or market any product which infringes the amended claims of Panacea patent, IN272351

DFC commits US $20 mn loan to Panacea Biotec towards capacity expansion for hexavalent vaccine

The wP-IPV-based hexavalent vaccination is an innovative immunization alternative to the current pentavalent and standalone IPV vaccines

ICMR and Panacea Biotec initiates Phase III clinical trial of DengiAll

The clinical trial will be conducted at 19 sites with 10,335 participants across India

Panacea Biotec launches EasyFourPol in India

Receives registration of Valganciclovir powder for oral solution in Germany

Panacea Biotec posts Q1 FY24 consolidated PAT at Rs. 10.98 Cr

Panacea Biotec has reported total income of Rs. 135.27 crores during the period ended June 30, 2023